Publication date: Available online 12 August 2017
Source:International Journal of Radiation Oncology*Biology*Physics
Author(s): Lisanne V. van Dijk, Charlotte L. Brouwer, Hans Paul van der Laan, Johannes G.M. Burgerhof, Johannes A. Langendijk, Roel J.H.M. Steenbakkers, Nanna M. Sijtsema
Backgroundand purpose: The aim of this study was to identify a surrogate marker for late xerostomia 12 months after radiotherapy (Xer12m) based on information obtained shortly after treatment.Materials and methodsDifferences in parotid gland (PG) were quantified in image biomarkers (ΔIBMs) before and 6 weeks after radiotherapy of 107 patients. By performing step-wise forward selection, ΔIBMs that were associated with Xer12m were selected. Subsequently, other variables, such as PG dose and acute xerostomia scores were added to improve the prediction performance. All models were internally validated.ResultsPrediction of Xer12m based on PG surface reduction (ΔPG-surface) was good (AUC=0.82). PG dose was related to ΔPG-surface (p<0.001, R2=0.27). The addition of acute xerostomia scores to the ΔPG-surface improved the prediction of Xer12m significantly and vice versa. The final model including ΔPG-surface and acute xerostomia had outstanding performance in predicting Xer12m early after radiotherapy (AUC=0.90).ConclusionPG surface reduction was associated with late xerostomia. The early post-treatment model with ΔPG-surface and acute xerostomia scores can be considered as surrogate marker for late xerostomia.
Teaser
The aim of this study was to identify a surrogate marker for late xerostomia 12 months after radiotherapy based on information obtained shortly after treatment. Differences in parotid gland (PG) were quantified in image biomarkers (ΔIBMs) before and 6 weeks after radiotherapy of 107 patients. The early post-treatment model with parotid gland surface reduction and acute xerostomia scores is a good candidate surrogate marker for late xerostomia.http://ift.tt/2vYudIj
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου